Ogsiveo (Nirogacestat Hydrobromide) Patent Expiration, LOE Window & CMS Spending

Ogsiveo (Nirogacestat Hydrobromide) by Springworks Therapeutics: FDA Orange Book core substance LOE 2039-08-09 (last listed 2043-05-19), 0 AB generics, $39.9M 2024 CMS Part D & Medicaid spend, and $29,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSpringworks Therapeutics
FDA Application & PathwayN217677 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2039-08-09
Last Listed Patent or Exclusivity Date2043-05-19
Orange Book Patents (*PED Extensions)29 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$39.9M
2024 Medicare Part D Spend$20.0M
2024 Medicaid Spend$19.9M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($29,000 intro WAC)